摘要
Abstract
Objective:To systematically evaluate the efficacy and safety of trastuzumab in adjuvant therapy for HER2-positive breast cancer.Methods:Computerized search was performed to identify prospective random control trials published both in the domestic and o-verseas during 1996 to 2013 comparing adjuvant chemotherapy with or without trastuzumab in HER2-positive breast cancer patients.Jadad grading standard was used to appraise the quality of the included studies.Review Manager 5.3 was used to conduct the Meta-analysis.Results:With 4 eligible Phase III clinical randomized controlled trials( Rcts) identified (2 of them were joint analysis) , this a-nalysis demonstrated that patients with HER2-positive breast cancer derived benefit in disease-free survival [HR=0.63,95%CI(0.50, 0.81),P<0.001], overall survival [HR=0.69,95%CI(0.56,0.86),P=0.001] from the addition of trastuzumab to adjuvant chemo-therapy, whereas trastuzumab bore a higher incidence of cardiac event[RR=5.09,95%CI(3.23,8.03),P<0.00001] and congestive cardiac failure [RR=5.32,95%CI(2.28,12.44),P=0.0001]as compared to the control group.However, the addition of trastuzum-ab made no significant difference in cardiac death.Conclusion: The curative effect of adjuvant trastuzumab is significantly better than chemotherapy alone in patients with HER2-positive breast cancer with cardiac toxicity increased.关键词
曲妥珠单抗/HER2阳性/乳腺癌/心脏事件/Meta分析Key words
Trastuzumab/HER2-positive/Breast cancer/Cardiac event/Meta-analysis分类
医药卫生
